$2.338
-0.098 (-4.18%)收盘时
XRTX 同业对比
In the context of the broader market, XRTX competes directly with industry leaders such as GELS and PCSA. With a market capitalization of $4.43M, it holds a significant position in the sector. When comparing efficiency, XRTX's gross margin of N/A stands against GELS's N/A and PCSA's N/A. Such benchmarking helps identify whether XORTX Therapeutics Inc is trading at a premium or discount relative to its financial performance.
XORTX Therapeutics Inc 财务表现
XORTX has shown mixed financial performance, with a recent net income of -808472 USD in Q1 2026 and a forward P/E of 0.9621, suggesting potential for recovery but also indicating ongoing losses.
Financials
FY2026Q1
YoY:
-14.55%
-823.30K
Operating Profit
FY2026Q1
YoY:
+15.72%
-808.47K
Net Income after Tax
FY2026Q2
YoY:
+10.53%
-1.05
EPS - Diluted
FY2026Q2
YoY:
+318.38%
-3.41M
Free Cash Flow
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。